Biograil biotechnology company logo representing the Danish developer of BIONDD oral drug delivery technology.
Biograil has secured €20 million to advance its capsule-based oral drug delivery technology toward Phase 1 clinical testing. The financing will support non-clinical studies and manufacturing preparations.

Denmark-based biotechnology company Biograil has closed a €20 million financing round to advance the clinical development of its oral drug delivery platform, BIONDD.

The financing was backed by Verve Ventures and Megatrend Invest, with High-Tech Gründerfonds (HTGF) participating through its HTGF Opportunity growth fund. HTGF previously led Biograil’s seed investment syndicate in 2019.

Founded in 2019 by Karsten Lindhardt and Nikolaj Skak, Biograil develops technology designed to administer medicines that would otherwise require injections. Lindhardt serves as CEO, while Skak is the company’s Chief Scientific Officer.

The company’s proprietary BIONDD platform uses a drug delivery device housed inside a standard-sized swallowable capsule. After the capsule dissolves in the stomach, the device is designed to attach to the stomach wall and deliver therapeutic substances directly into the tissue.

Manufactured using injection-moulding technology, the platform is being developed for biologics and other complex pharmaceutical compounds that are difficult to administer through conventional oral formulations. Biograil remains at the preclinical development stage.

The new financing will support preparations for Phase 1 clinical testing, including non-clinical studies conducted under Good Laboratory Practice (GLP) standards and the establishment of a Good Manufacturing Practice (GMP) manufacturing process.

Biograil plans to complete these development milestones ahead of a larger financing round targeted for 2027. The company has also received non-dilutive financing through strategic partnerships.

In July 2025, Biograil announced the €8.5 million first close of a financing round led by Verve Ventures, with participation from existing investors and new investor Acondis GmbH.

Its broader investor syndicate includes Eli Lilly and Company, Sanner Ventures, Evonik Venture Capital, Anobis GmbH and Roquette Ventures, alongside Verve Ventures, Megatrend Invest and HTGF.

Get the latest startup funding news in your inbox.

We don’t spam! Read our privacy policy for more info.

Share